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Thesuccesssince2004instabilisingtheglobaltuberculosis
(TB) epidemic is being undermined by the emergence of
drug-resistant TB (DR-TB). This form of TB is more difﬁ-
cult and costly to diagnose, treat and cure. In 2009, the
World Health Assembly declared DR-TB a ‘global public
healththreat’thatthreatenstounderminethesustainabil-
ity of TB programmes.1 This global resolution aims to
achieve universal access to diagnosis and treatment of
DR-TB by 2015.2 However, only 11% of notiﬁed multi–
DR-TB (MDR-TB) cases received treatment in 2009.3 The
response to DR-TB must focus on the strengthening of
national TB programmes and on the scaling up of services
to diagnose patients and make treatment accessible. We
need to pursue the goal of universal access to these ser-
vices,coupledwiththeurgentdevelopmentofnewdrugs,
point of care diagnostics and tools to achieve the ultimate
aim of eradication of the disease.
DR-TB includes MDR-TB, deﬁned as resistance to at
least isoniazid and rifampicin – the two most efﬁcacious
drugs for treating TB – and extensively DR-TB (XDR-TB),
which has additional resistance to a ﬂuoroquinolone
(levoﬂoxacin, oﬂoxacin, moxiﬂoxacin) and one or more
second-line injectable antibiotics (kanamycin, amikacin
or capreomycin) – the most effective of the second-line
drugs. It also includes monoDR-TB or polyDR-TB – resis-
tance to any other ﬁrst-line drugs that is not MDR-TB or
XDR-TB. These patterns of resistance are important to
report, as the standard 6-month TB treatment regimen
cannot be used if present. Often second-line drugs are
required, though rarely available in most settings, result-
ing in treatment failure and ampliﬁcation of resistance.
TB in the former Soviet Union
The former Soviet Union comprises the Russian Federa-
tion, parts of Eastern Europe, central Asia and the Cau-
casus and contains 12 of the 27 global high-burden
MDR-TB countries. The TB epidemic in this region is
different to Africa and other areas in Asia in its context
(middle income, low HIV prevalence) and aetiology (col-
lapse of health systems, unregulated drugs and transmis-
sion in prisons). During the Soviet era, Russia possessed a
well-developed health system with innovation and
development. The Soviet republics were part of a large
central organisational structure with Moscow at the
centre. Health structures were vertical, with hospitals for
each specialty. The collapse of the Soviet Union in 1991
brought a transition to a market economy and open
society. However, socio-economic conditions worsened,
and there was collapse and decentralisation of the health
system.4 Funding for health was not a priority, in particu-
lar TB. The republics and regions (or Oblasts) were
devoid of functioning national health/TB programmes.
The pharmaceutical industry was deregulated, leading to
poor-quality drugs, freely available private TB drugs and
frequent stock-outs in government facilities. The real
nidus for TB was the overcrowded prisons with separate
and weaker healthcare systems. Finally, there was an
initial absence of international health factors, particularly
with the relics of political isolation from the West. In
Russia, TB mortality almost doubled in 20 years to 1999
and was the highest in Europe at 20 per 100 000.4 Drug
resistance reached rates close to the highest in the world.
Abkhazia, a territory in the Caucasus, nestled between
the Black Sea, Russia and Georgia, was once the seaside
jewel in the crown of the Soviet empire. Since a horriﬁc
ethnic conﬂict in 1992, it has become a ‘frozen state’ –
largely unrecognised by the international community
because of its self-declared autonomy from Georgia.5
Abkhazia is isolated geopolitically and under economic
sanction. Their health system functions poorly, and a
new threat has emerged – DR-TB. Médecins Sans Fron-
tières (MSF) has supported the local health authorities in
Abkhazia, Georgia and the region in treating patients
with DR-TB since 2000.
I ﬁrst met Aslana when he presented to the TB hospital
in Sukhum(i), Abkhazia with cough and fevers. This
30-year-old Abkhazian man had been imprisoned in
overcrowded condition in Russia for 13 years where he
acquired tuberculosis. He was treated with multiple
regimens with partial resolution of symptoms,
however when he was released and went back to live
with his family, his symptoms returned. His sputum
was sent on a 20-day journey to the reference labora-
tory in Belgium. Three months later, after the slow
diagnostic culture process – the results of drug-
susceptibility testing showed he had extensively
drug-resistant tuberculosis (XDR-TB). Despite his
understandable skepticism of doctors and TB treat-
ment, he started taking multiple drugs as prescribed.
aNames of patients have been altered for publication.
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intolerable, and he was soon vomiting every day. In
addition, he was asked to remain in hospital while
infectious and smear-positive. For Aslan the outlook
was bleak: he had no livelihood. He knew he would die
from his TB. He did not continue his treatment. The
local doctors and MSF team screened his family and,
unfortunately, his 16-year-old niece, a household
contact, was infected with TB, most likely XDR.
In Abkhazia, MSF facilitated drug susceptibility
testing during 2000–2010: 18% of all suspected cases
(smear positive and negative) had MDR-TB, including
2% with XDR-TB. Community transmission or
primary resistance of DR-TB is evidenced by the fact
37% of patients with MDR-TB never had TB before.
Only one third of these patients had a known contact
with another person with MDR-TB.
Cure of DR-TB is possible, necessary
and cost-effective
Recent modelling studies have shown that if MDR-TB is
not treated or addressed, it will out-compete the drug-
susceptible strains and become the predominant type.6
Treatment and care of patients with DR-TB are possible,
achievable and necessary. The best DR-TB programmes
have cure rates of 80% for MDR-TB and 60% for XDR-
TB.7 The successes of current programmes are moderate.
Globally, an average of 62% of patients are cured or
complete treatment, 13% default, and the remainder fail
or die.8
Treatment of DR-TB requires ﬁnancial investment –
mostly drugs, but also for diagnostics, infection control,
patient support and directly observed therapy (DOT)
staff. First-line TB drugs cost US$19 per patient for the
6-month treatment course.9 Second-line TB drugs are
available for approved programmes through the Global
Drug Facility. This reduces drug costs from around
$20 000 per patient to $4400–$9000.10 Treatment of
MDR-TB, however, is a cost-effective public health inter-
vention, even in low- and middle-income settings.11,12
The treatment of DR-TB is challenging for health pro-
viders and an arduous journey for the patient. Current
treatment regimens are constructed with second-line
drugs – old compounds that are less efﬁcacious, more
toxic and more costly.2 The evidence base for guidelines is
of low quality with no randomised controlled trials. In
2011, the World Health Organization (WHO) published
an update to its DR-TB guidelines, which included a
meta-analysis of the three published systematic reviews.
Current principles of treatment include:13,14
• At least four likely effective drugs should be used
when MDR-TB is suspected
• Regimens should include at least pyrazinamide, a
ﬂuoroquinolone, a parenteral agent, ethionamide
(or prothionamide), and either cycloserine or p-
aminosalicylic acid
• Treatment duration is at least 20 months. The inten-
sive phase involves the use of an injectable agent for at
least 8 months and 4 months after culture conversion.
The global drug development pipeline for TB remains
insufﬁcient to address the needs of treatment.15 The last
novel compound invented for ﬁrst-line TB therapy was
rifampicin in 1963, and in the past decade, only six com-
pounds have been making the progression through clini-
cal trials. The most exciting development has been the
development of a pilot 9-month short-course regimen
for MDR-TB in Bangladesh, with cure rates of almost
90%.16 It is currently being explored further in a multi-
centre study, and preliminary reports from Africa are
promising.
Treating individuals with DR-TB –
beyond the drugs
Patient support is an integral part of DR-TB treatment
and should be directly observed by a treatment supporter.
The medical treatment should be supported by nutrition
(food packages), health education, social (transport) and
psychological support. Implementing these models of
care in contexts where health systems are weak is chal-
lenging. A community-based model of care involves the
DOT provider having a central role as a treatment sup-
porter and avoiding prolonged hospitalisation. Such a
model has been shown to be effective in resource-limited
environments and is recommended by the WHO.17,18
In the programme in Abkhazia a multi-disciplinary
approach has been adopted by MSF and the local TB
hospital, with weekly team meetings between physi-
cians, nurses, TB educators and social workers. After
initial hospitalisation, patients were supported through
treatment with ﬂexible treatment delivery – commu-
nity DOT providers, transport subsidy, food packages
and home modiﬁcation for infection control. There
is an ongoing attempt to link TB care between the
health and prison systems. However, these efforts
are constrained by the geopolitical situation in this
post-conﬂict setting. There is a limited programmatic or
strategic approach to TB care and local capacity is low.
Around 20% of patients default from treatment
and poor adherence has resulted in ampliﬁcation of
resistance.19 Patients are from vulnerable groups – 41%
of DR-TB patients had a history of incarceration, 54%
harmful levels of alcohol, 11% a history of intravenous
drug use and 3% were homeless. In addition, there
Editorial
© 2011 The Authors
Internal Medicine Journal © 2011 Royal Australasian College of Physicians 806were internally displaced persons from the conﬂict.
Conversely, MSF has successfully scaled-up and
handed over a DR-TB program in the town of Zugdidi,
on Georgian side of the ‘frozen border’ to the national
TB program.
DR-TB on the global stage
Each year an estimated 500 000 people acquire new
infection with MDR-TB and 150 000 die.3 The incidence
is rapidly increasing each year.20,21 Currently, there are an
estimated 1.5 million people living with MDR-TB, includ-
ing 50 000 with XDR-TB.22 It is important to note that
global data quality on drug resistance is poor. It is limited
by inaccurate reporting/recording and inadequate labo-
ratory capacity for drug-susceptibility testing. In particu-
lar, resistance is largely unquantiﬁed in Africa with only
12 of 46 countries having conducted a national DR
survey since 2000.9 Furthermore, WHO data underesti-
mates the true burden of DR-TB, as it is based only on
drug-susceptibility testing from smear-positive cases,
neglecting smear-negative and extra-pulmonary TB.23
Barriers to scaling up comprehensive
TB care
TheprogrammaticmanagementofDR-TBrequiresacom-
prehensive public health approach. It is built on having
goodbasicTBcontroltopreventDR-TBemergence.Thisis
an enormous challenge for resource-constrained coun-
tries, and the current assistance of the international com-
munity is far from adequate. The challenges are
• Funding gaps: US$7.1 billion is needed to treat
MDR-TB for the period of 2011–2015.2
• Limited local political will.
• Lack of skilled human resources.
• Lack of laboratory capacity for diagnosis and reliance
on specialised tests: the new geneXpert rapid test (real
time PCR) can diagnose MDR-TB in less than 2 h but
requires substantial ﬁnancial and human capacity
investments.24
• Inadequate production and high costs of second-line
drugs.
• Urgent need for more effective and less toxic drugs,
and shorter treatment regimens, but there is limited
investment in new drug development or trials of shorter
regimens.
• Need for the development of innovative context-
adapted community-based care models.
• Ineffective infection control measures are a key driver
of the DR-TB epidemic, including in healthcare facilities.
Infection control measures need to be in place in all
healthcare settings, together with initiatives to reduce
community transmission, including point of care diag-
nostics and effective treatment.
Conclusions
Drug-resistant tuberculosis is an increasing problem that
threatens the substantial gains in TB control that have
been made globally in the last 20 years. Despite difﬁcul-
ties, DR-TB can be successfully treated with currently
available diagnostics and treatments. The WHO Stop TB
Plan for 2011–2015 calls for universal access to diagnosis
and treatment for DR-TB by 2015. As can be seen from
Abkhazia and many other countries, however, the gaps
between guidelines and on the ground implementation
remain large. The threat of DR-TB is imminent in the
Australasian region – Simpson highlighted the alarming
rates of DR-TB in Papua New Guinea in last month’s
editorial in the Internal Medicine Journal.25 Without urgent
action and political commitment from donor agencies,
the Global Fund and governments, the ambitious goals
set will not be reached.
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